Abstract: The present invention is concerned with the use of a compound of formula (I) ##STR1## wherein --W-- is ##STR2## wherein Z is --V(CH.sub.2).sub.b CO.sub.2 H where b is 1 or 2 and V is oxygen when b is 1 or methylene when b is 2;X is hydrogen, cyano, or --C.tbd.CH; andthe dotted line represents an optional double bond;and physiologically functional derivatives thereof,in the treatment of congestive heart failure.

Abstract: Synergistic combinations of nucleoside derivatives, pharmaceutical formulations containing said combinations and use of the combinations in the treatment of retroviral infections are disclosed.

Abstract: The present invention relates to the treatment and prophylaxis of Pneumocystis carinii infections with 2-[4-(4-chlorophenyl)cyclohexyl-3-hydroxy-1,4-naphthoquinone.

Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein R, R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl;R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-6 alkyl (including cycloalkyl) and aryl (wherein the alkyl or aryl group, which latter includes benzyl, is optionally substituted by one or more atoms or groups independently selected from halogen, C.sub.1-4 alkyl and aryl), provided R.sup.3 benzyl or substituted benzyl when R.sup.4 =H;m is an integer of from 0 to 2;n is an integer of from 0 to 3;(W) is a group of formula (i), (ii), (iii), or (iv) ##STR2## wherein Y is selected from oxygen, methylene and >N--R.sup.5, where R.sup.5 is hydrogen, C.sub.1-4 alkyl, or benzyl, Z and Z' are independently selected from >C.dbd.O, >C.dbd.

Abstract: A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.

Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. The invention also relates to pharmaceutical formulations and processes for the preparation of compounds according to the invention.

Abstract: The present invention relates to a 3'-substituted pyrimidine nucleoside and its use in medical therapy, particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations.

Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen or C.sub.1-4 alkoxy;R.sub.2 is carbonyl, hydroxymethylene, or methylene; andR.sub.3 is hydrogen or hydroxy;and salts thereof, provided that when R.sub.1 is hydrogen and R.sub.2 is carbonyl, R.sub.3 is not hydroxy, with processes for preparing same and with their use in medicine for the treatment of hypertension.

Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Also provided are pharmaceutical formulations and processes for the production of the compounds of the invention.

Abstract: This invention relates to certain 2'-fluoro nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the production of the compounds according to the invention.

Abstract: Novel antiprotozoal naphthoquinones having the general formula ##STR1## (wherein either R.sup.1 is hydrogen and R.sup.2 is selected from C.sub.1-6 alkoxy, aralkoxy, C.sub.1-6 alkyl-C.sub.1-6 alkoxy, phenyl substituted by one or two groups selected from halogen and C.sub.1-6 alkyl, halogen and perhalo-C.sub.1-6 alkyl; or R.sup.1 and R.sup.2 are both C.sub.1-6 alkyl or phenyl; and n is 0 or 1) and salt thereof. The compounds of formula (I) are useful for the treatment or prophylaxis of protozoal diseases including malaria, theileriosis and coccidiosis. Various processes for preparing compounds of formula (I) are described.

Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.

Abstract: This invention describes the preparation and use of anticonvulsant agents. In particular, triazolopyridine compounds are described which have utility in the treatment of epilepsy in mammals.

Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especiallly viruses of the herpes group.

Abstract: The present invention relates to a 3'-substituted pyrimidine nucleoside and its use in medical therapy, particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations.

Abstract: The present invention relates to 3'-azido purine nucleosides and their use in medical therapy, particularly for the treatment of human immunodeficiency virus and hepatitis B virus infections, to methods for their preparation and to compositions containing them.

Abstract: The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --;R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, orR is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; andthe dotted line represents an optional double bond;or of a physiologically acceptable salt or acid derivative thereof.Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: An aqueous parenteral solution of tissue-plasminogen activator, in which the pH is from 2 to 5.

Abstract: A composition for use in an aqueous environment which .[.comprise.]. .Iadd.comprises .Iaddend.a formulation containing a water-soluble pharmaceutically beneficial agent, a water-insoluble, water-permeable film coating surrounding the formulation, and particulate, water-soluble, pore-forming material dispersed within the film coating.The questions raised in reexamination request No. 90/001,344, filed Oct. 5, 1987, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).